Passionflower for Anxiety Relief
In the landmark Akhondzadeh 2001 randomized double-blind trial published in the Journal of Clinical Pharmacy and Therapeutics, 36 outpatients with generalized anxiety disorder (GAD) were assigned to either passionflower extract (45 drops/day) or oxazepam 30 mg/day. After four weeks, both treatments produced statistically equivalent reductions in Hamilton Anxiety Rating Scale scores — passionflower matched the benzodiazepine on the primary anxiolytic endpoint. The trial also reported significantly more problems with impairment of job performance on oxazepam than on passionflower (a 2007 Cochrane review classed this as an outcome not planned in advance and found it did not reach statistical significance in its own analysis). This finding — similar anxiety relief with fewer reported job-performance problems — is the central reason passionflower retains a place in clinical practice despite the much wider use of prescription benzodiazepines. The 2008 Movafegh pre-operative trial extended this to a different anxiety context: 60 patients undergoing ambulatory surgery received either passionflower extract 500 mg or placebo 90 minutes pre-operatively, and the passionflower group had significantly lower anxiety scores on a numerical rating scale over the 90 minutes after the dose. This page walks through the trial evidence, the practical clinical positioning, and the situations where passionflower is and is not the right anxiolytic choice.
Table of Contents
- The Akhondzadeh 2001 GAD Trial vs Oxazepam
- The Movafegh 2008 Pre-Operative Anxiety Trial
- Dental-Procedure Anxiety Trials
- The Anxiolytic Mechanism: Chrysin and Benzoflavones
- Situational vs Generalized Anxiety — Dosing Differences
- Why Cognitive Function Is Preserved
- Clinical Positioning Between Chamomile and Kava
- Practical Dosing, Forms, and Onset
- Combination Protocols (Lavender, Lemon Balm, L-Theanine)
- Cautions and Interactions
- Key Research Papers
- Connections
- Featured Videos
The Akhondzadeh 2001 GAD Trial vs Oxazepam
The single most influential clinical trial of passionflower was conducted by Shahin Akhondzadeh and colleagues at the Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, and published in the Journal of Clinical Pharmacy and Therapeutics in 2001. The study was a double-blind randomized controlled trial designed to address a clinically important question: does an herbal anxiolytic match a standard benzodiazepine for generalized anxiety disorder?
Thirty-six outpatients meeting DSM-IV criteria for generalized anxiety disorder were randomized to either:
- Passionflower extract, 45 drops per day of a standardized tincture, plus placebo tablets
- Oxazepam (a benzodiazepine in the same class as diazepam) 30 mg per day, plus placebo drops
The double-blind design used dummy oxazepam tablets in the herbal arm and dummy passionflower drops in the benzodiazepine arm so that neither patients nor investigators knew which active treatment each subject was receiving. Anxiety was measured weekly with the Hamilton Anxiety Rating Scale (HAM-A), the gold-standard clinician-administered instrument for generalized anxiety severity. The trial report also describes problems with job performance; the 2007 Cochrane review that re-examined the trial describes job performance as a post-hoc outcome (one not planned before the trial began).
After four weeks, the results were:
- HAM-A scores fell similarly in both groups, with no statistically significant difference between treatments — passionflower matched oxazepam on the primary anxiolytic endpoint
- Oxazepam showed a more rapid onset of action
- The trial report states that significantly more problems relating to impairment of job performance were encountered with oxazepam than with passionflower; the 2007 Cochrane review, analysing the same data, found this difference did not reach statistical significance
- No serious adverse events occurred in either arm; dropouts were comparable
The trial has been criticized for its small size (36 patients) and single-site design, and the dosing of the oxazepam arm (30 mg/day) is on the lower end of typical clinical practice. Even with those caveats, the clinical signal — equivalent anxiolysis with significantly less daytime impairment — has been remarkably durable and has been cited in essentially every subsequent review of herbal anxiolytics. The trial established passionflower's clinical credibility as a real option for generalized anxiety in patients who cannot tolerate benzodiazepine sedation.
What is not known: the only Cochrane review of passionflower for anxiety (Miyasaka 2007) found just two eligible randomized trials, with 198 people in total. It concluded that these trials are too few to draw any conclusions, and that larger trials comparing passionflower with placebo and with other medicines, including antidepressants, are needed.
The Movafegh 2008 Pre-Operative Anxiety Trial
The Movafegh 2008 study (Anesthesia & Analgesia) addressed a different but practically important anxiety context: the acute situational anxiety patients experience in the 90 minutes before surgery. This is normally treated with intravenous midazolam at the time of preoperative line placement, but oral premedication options that do not require intravenous (IV) access are clinically useful, particularly for outpatient procedures.
The trial randomized 60 patients undergoing ambulatory (same-day) surgery, 30 per group, to receive either:
- Passiflora incarnata extract 500 mg orally, 90 minutes before surgery
- Identical-appearing placebo capsules, 90 minutes before surgery
Anxiety and sedation were scored on a numerical rating scale before the dose and 10, 30, 60 and 90 minutes after it. Psychomotor performance (Trieger Dot Test and Digit-Symbol Substitution Test) was tested on arrival in the operating room and 30 and 90 minutes after the breathing tube was removed (tracheal extubation, meaning the operations were done under general anesthesia). The time from arrival in the recovery unit to discharge home was also recorded.
Results:
- The passionflower group had numerical-rating-scale anxiety scores significantly lower than placebo (p < 0.001); sedation scores and discharge time were similar in the two groups
- Psychomotor performance scores were not impaired in the passionflower group — in contrast to the typical cognitive slowing seen with midazolam premedication
- Intraoperative hemodynamics were stable in both groups; no anesthetic complications attributable to passionflower
- No serious adverse events; sedation level was rated as light and easily arousable
The Movafegh trial established passionflower as a real option for outpatient pre-procedural anxiety where intravenous midazolam is not desired and where intact psychomotor function in the post-anesthesia recovery period matters — particularly for patients being discharged home shortly after surgery.
A separate 2012 trial by Aslanargun and colleagues in Turkey studied 60 patients aged 25-55 before spinal anesthesia, using the State-Trait Anxiety Inventory (STAI). Anxiety rose less between baseline and the moment just before spinal anesthesia in the passionflower group than in the placebo group, and passionflower did not change psychomotor test results, sedation level or hemodynamics (blood pressure and heart rate).
Dental-Procedure Anxiety Trials
The dental literature has produced multiple positive trials of passionflower for the specific context of dental-chair anxiety. Dental anxiety affects an estimated 9-15% of adults in industrialized populations to a degree that delays or prevents needed care, and benzodiazepines are routinely used as oral premedication for anxious patients undergoing extractions, periodontal surgery, and root canals.
Notable trials and reviews:
- Dantas LP et al. (2017) — a randomized, double-blind crossover trial in 40 volunteers who had both lower wisdom teeth (mandibular third molars) removed, one side at a time, receiving passionflower 260 mg or midazolam 15 mg by mouth 30 minutes before each surgery. Anxiety was assessed with questionnaires and with heart rate, blood pressure and oxygen saturation. There were no significant differences between the two in blood pressure, heart rate or oxygen saturation, and over 70% of volunteers said they felt quiet or only a little anxious with either drug. With midazolam, 20% reported amnesia (no memory of the procedure at all), while passionflower showed little or no effect on memory.
- Kaviani N et al. (2013) — a single-blind trial in 63 patients with moderate to severe anxiety who needed gum (periodontal) treatment, split into three groups of 21: passionflower drops, placebo drops, or no treatment. The mean anxiety score fell from 12.09 to 8.47 with passionflower, from 12.00 to 10.52 with placebo, and from 11.66 to 11.23 with no treatment; the passionflower group differed significantly from both other groups (p < 0.0001). The authors described it as a first study needing larger trials to confirm it.
- Christoffoli MT et al. (2021) — a randomized, double-blind, split-mouth crossover trial in 20 patients (mean age 22.5) having lower wisdom teeth removed, comparing passionflower with midazolam. Heart rate was best controlled with passionflower at one stage of surgery (p = 0.036), and side effects such as drowsiness, muscle relaxation and dizziness were reported more with midazolam.
- Lima Neto TJ et al. (2025) — 30 patients aged 16-35 having impacted wisdom teeth removed were randomly given passionflower, midazolam or placebo (10 per group) 30 minutes before surgery. Anxiety scores and most physical measures did not differ between the groups; diastolic blood pressure was higher with passionflower. After surgery, the stress hormone cortisol in saliva was significantly lower with both passionflower and midazolam than with placebo, with no difference between passionflower and midazolam.
- Araújo JO et al. (2021) — a systematic review of oral sedation for dental treatment in adults covered 12 randomized trials (327 patients): nine of benzodiazepines and three of herbal medicines. It found that midazolam 15 mg reduced anxiety more than passionflower 260 mg, while more patients reported side effects with midazolam 15 mg. The authors noted that the findings are limited by the quality of the included studies and that more trials are needed.
The clinical implication: passionflower has been tested head-to-head against benzodiazepines (oxazepam, midazolam) in two patient populations — generalized anxiety disorder and dental extraction — while the pre-surgical trials compared it with placebo. On anxiety, results range from no significant difference to a greater anxiety reduction with midazolam; memory loss, drowsiness and other side effects were reported less often with passionflower. The 2007 Cochrane review concluded that the randomized trials of passionflower for anxiety are too few in number to permit any conclusions.
The Anxiolytic Mechanism: Chrysin and Benzoflavones
The primary anxiolytic mechanism of passionflower is positive allosteric modulation of the gamma-aminobutyric acid-A receptor at the benzodiazepine binding site. This was originally demonstrated by Wolfman and colleagues in 1994 when they isolated chrysin (5,7-dihydroxyflavone) from Passiflora coerulea and showed it bound the central benzodiazepine receptor with measurable affinity. Chrysin is also present in Passiflora incarnata, along with apigenin (the chamomile flavone), luteolin, and other flavones that contribute to the overall flavonoid pool.
A second active scaffold was proposed in 2001 by Dhawan and colleagues: a fraction of the methanol extract of Passiflora incarnata was anxiolytic at 10 mg/kg in mice in the elevated plus maze, and they proposed that a compound with a benzoflavone core was responsible. Their later papers describe a tri-substituted benzoflavone moiety from the plant that was anxiolytic at 10 mg/kg by mouth in mice (animal studies only).
The combined effect of chrysin and benzoflavones at the gamma-aminobutyric acid-A benzodiazepine site is to potentiate the inhibitory effect of endogenous gamma-aminobutyric acid (GABA) — the same fundamental mechanism as diazepam or oxazepam, but with much lower binding affinity and partial-agonist character. The pharmacologic consequence is that passionflower amplifies normal GABAergic inhibition modestly rather than producing the powerful clamping effect of a full benzodiazepine agonist. This is why anxiety is reduced but cognition, motor coordination, and arousal are preserved.
For a full pharmacology discussion of the binding site, the harman alkaloids, and the theoretical MAO-A interaction, see the gamma-aminobutyric acid Modulation deep-dive page.
Situational vs Generalized Anxiety — Dosing Differences
The trial evidence supports passionflower for two distinct clinical contexts that require different dosing strategies:
- Situational (acute) anxiety — pre-procedural anxiety, public-speaking nerves, acute stress reactions. The Movafegh 500 mg single-dose protocol is the prototype: a single moderate-to-high dose 60-90 minutes before the anxiety-provoking event. Effect is felt within 30-60 minutes, peaks around 60-90 minutes, and lasts 4-6 hours. No tapering needed because there is no chronic dosing.
- Generalized anxiety disorder (chronic) — daily dosing over weeks. The Akhondzadeh protocol used 45 drops/day of standardized tincture (roughly equivalent to 300-450 mg dried herb daily); other trials have used 250-800 mg of standardized extract divided into two or three doses through the day. Full clinical effect emerges over 2-4 weeks rather than immediately, much like selective serotonin reuptake inhibitors (SSRIs) but typically faster.
The choice of formulation matters. Glycerin tinctures and aqueous teas extract a different flavonoid profile than ethanol tinctures or hydroethanolic dry extracts. The trials that produced positive results used standardized hydroethanolic extracts where the flavonoid content was characterized; bulk dried-leaf preparations of unknown extraction profile may not produce equivalent effect.
Why Cognitive Function Is Preserved
The repeated finding that passionflower reduces anxiety without impairing cognition or motor coordination is mechanistically explained by the partial-agonist, low-affinity binding profile at the gamma-aminobutyric acid-A benzodiazepine site. Full benzodiazepine agonists like diazepam or alprazolam occupy a high fraction of the available benzodiazepine binding sites at therapeutic doses, producing strong potentiation of gamma-aminobutyric acid-A current. The result is global cortical and brainstem inhibition — the anxiolytic effect is real, but so is the cognitive slowing, motor incoordination, amnestic effect, and sedation. With chronic use, downregulation of gamma-aminobutyric acid-A receptor density produces tolerance and physiologic dependence.
Passionflower's chrysin and benzoflavones bind the same site with much lower affinity. At therapeutic doses, only a small fraction of available benzodiazepine binding sites are occupied, and the partial-agonist character means even occupied receptors are only partially activated. The result is a modest amplification of basal GABAergic inhibition that is sufficient to reduce pathologic anxiety but insufficient to produce the global cortical depression of full benzodiazepine agonism. Cognition, attention, motor coordination, and arousal remain near baseline.
There is also no documented tolerance development with passionflower over weeks-to-months of clinical use, which fits the low-occupancy, partial-agonist binding profile. Discontinuation produces no documented withdrawal syndrome — another contrast with benzodiazepines, where abrupt discontinuation after sustained use causes rebound anxiety, insomnia, and in severe cases, seizures.
Clinical Positioning Between Chamomile and Kava
Passionflower occupies a specific niche in the botanical anxiolytic spectrum that is best understood by comparison with its closest neighbors:
- Chamomile (Matricaria recutita) — the flavone apigenin binds the gamma-aminobutyric acid-A benzodiazepine site, mechanistically very similar to chrysin. Effect is gentler and more subtle than passionflower; chamomile is commonly used for low-grade situational anxiety, as a sleep aid for mild insomnia, and in children. The 2009 Amsterdam GAD trial demonstrated chamomile produces clinically meaningful anxiety reduction over 8 weeks, but the effect size is smaller than passionflower's.
- Passionflower — moderate effect, head-to-head trial evidence against benzodiazepines, the strongest clinical evidence base in this class. Trials have tested it in generalized anxiety, before surgery and before dental procedures, where preserved thinking and coordination matter.
- Kava (Piper methysticum) — kavalactones produce significantly stronger anxiolysis than passionflower, with several positive head-to-head trials against benzodiazepines and the 2003 Pittler and Ernst Cochrane meta-analysis (6 trials, 345 people) finding Hamilton Anxiety scores about 5 points lower with kava extract than with placebo. The trade-off is the well-documented but uncommon risk of severe hepatotoxicity, which led to regulatory bans in much of Europe in the early 2000s and remains a real consideration despite later analyses suggesting the risk is concentrated in particular kava cultivars and extraction methods. Practitioners describe Kava as an option for moderate-to-severe anxiety when passionflower has not helped; the liver-injury reports are the main safety concern with it.
For severe or treatment-resistant anxiety disorder, prescription pharmacotherapy — selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors (SNRIs), buspirone, or in selected cases benzodiazepines — remains the standard of care. Passionflower is not a replacement for these in patients with severe panic disorder, severe GAD with substantial functional impairment, or anxiety with comorbid major depressive disorder. It is a useful adjunct or first-line option for mild-to-moderate anxiety where benzodiazepine side effects are unacceptable.
Practical Dosing, Forms, and Onset
Standardized extract dosing, based on the published trial literature and the European Medicines Agency (EMA) monograph:
- Standardized hydroethanolic dry extract — 200-800 mg per day, divided into 2-3 doses, or as a single 500 mg pre-event dose for situational anxiety
- Tincture (1:5 in 45% ethanol) — 2-4 mL three times daily for chronic dosing; 5-8 mL single dose for situational anxiety
- Tea (dried herb infusion) — 1-2 grams dried herb steeped in hot water for 10 minutes, 2-3 cups per day. The aqueous infusion extracts a less concentrated flavonoid profile than tinctures but is the traditional form for sleep and evening relaxation
- Glycerin tincture — for alcohol-free formulation, typically dosed at 1.5x the equivalent ethanol tincture amount
Onset of effect for acute anxiolysis is 30-60 minutes after an oral dose; peak effect at 60-120 minutes; duration of effect 4-6 hours per dose. For chronic generalized anxiety, expect initial subjective benefit within several days but full effect over 2-4 weeks of consistent daily dosing.
Quality matters substantially. The flavonoid content of dried passionflower herb varies widely depending on harvest timing, plant part (leaves vs whole aerial parts vs flowers), drying method, and storage. European Medicines Agency monograph products are standardized to flavonoid content (typically expressed as vitexin equivalents); these are the preferred preparations for clinical use. Bulk dried herb of unknown standardization may produce inconsistent effects.
Combination Protocols (Lavender, Lemon Balm, L-Theanine)
Passionflower combines well with several other gentle nervines for additive or complementary anxiolytic effect without crossing into benzodiazepine-level sedation:
- Passionflower + Lavender (a standardized oral lavender oil preparation) — lavender works through linalool-mediated voltage-gated calcium channel modulation, a completely different mechanism from passionflower's gamma-aminobutyric acid-A approach. Trials of a standardized oral lavender oil preparation reported efficacy comparable to lorazepam in generalized anxiety disorder. Combining passionflower with that lavender oil preparation (80-160 mg) is described as a multi-mechanism anxiolytic combination without redundant pharmacology.
- Passionflower + Lemon Balm (Melissa officinalis) — lemon balm contains rosmarinic acid which inhibits gamma-aminobutyric acid transaminase (the enzyme that degrades gamma-aminobutyric acid), raising synaptic gamma-aminobutyric acid concentration. Pairing this with passionflower's receptor potentiation produces a synergistic effect on overall GABAergic tone.
- Passionflower + L-theanine — the amino acid analog from green tea modulates glutamate/N-methyl-D-aspartate (NMDA) signaling and increases alpha brain-wave activity. Combined with passionflower for situational anxiety with a cognitive-clarity profile (e.g., for public speaking anxiety where alertness matters).
- Passionflower + Magnesium glycinate — magnesium is required for normal gamma-aminobutyric acid-A receptor function and N-methyl-D-aspartate receptor modulation. Magnesium repletion in deficient individuals can substantially improve anxiety symptoms; passionflower works better against a magnesium-replete background.
- Passionflower + Valerian — classic European phytopharmaceutical combination, primarily for sleep but also used for evening anxiety. The Schulz sleep studies tested valerian alone, not this combination; a 2013 trial in India tested a valerian-passionflower-hops tablet against the sleeping pill zolpidem. Detail on the Sleep Quality page.
For comprehensive natural approaches to anxiety, see our Natural Anxiety Relief page.
Cautions and Interactions
- Benzodiazepines and Z-drugs — theoretical additive sedation, though clinically the combination is mild because passionflower's contribution is modest. The concern is greatest in elderly or frail people, who are the most sensitive to added sedation.
- Alcohol — additive central nervous system (CNS) depression. Significant alcohol intake adds to passionflower's sedation, which matters most for driving or operating machinery.
- Selective serotonin reuptake inhibitors and monoamine oxidase inhibitors (MAOIs) — theoretical concern from the harman beta-carboline alkaloid content (weak MAO-A inhibition). Clinical reports of serotonin syndrome with passionflower alone are essentially absent, but the theoretical interaction is worth respecting in patients on prescribed monoamine oxidase inhibitors. Discussed in detail on the gamma-aminobutyric acid Modulation page.
- Pregnancy and breastfeeding — insufficient safety data for routine use. The harman alkaloid content has theoretical uterine-stimulant effects. There is no safety data supporting its use in pregnancy, and breastfeeding data are limited.
- Surgery — a common conservative practice is to stop passionflower 1-2 weeks before scheduled surgery because of a possible additive effect with general anesthesia; this practice is probably overcautious but standard.
- Children — insufficient safety data for routine use in young children. The Akhondzadeh attention-deficit/hyperactivity disorder (ADHD) pilot used passionflower in school-age children with apparent good tolerance, but routine pediatric use is not established.
- Liver disease — rare case reports of hepatotoxicity associated with multi-herb passionflower-containing formulations exist but causality is unclear. No signal in clinical trials of standardized monoherb passionflower preparations.
- Cannabis and other sedating herbs — additive sedation; the sedating effects of each add together.
Key Research Papers
- Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M (2001). Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26(5), 363-367. — PubMed PMID: 11679026
- Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M (2008). Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesthesia & Analgesia, 106(6), 1728-1732. — PubMed PMID: 18499602
- Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU (2012). Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. Journal of Anesthesia, 26(1), 39-44. — PubMed PMID: 22048283
- Dantas LP, de Oliveira-Ribeiro A, de Almeida-Souza LM, Groppo FC (2017). Effects of passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction. Medicina Oral Patologia Oral y Cirugia Bucal, 22(1), e95-e101. — PubMed PMID: 27918731
- Kaviani N, Tavakoli M, Tabanmehr M, Havaei R (2013). The efficacy of Passiflora Incarnata Linnaeus in reducing dental anxiety in patients undergoing periodontal treatment. Journal of Dentistry (Shiraz), 14(2), 68-72. — PubMed PMID: 24724122
- Miyasaka LS, Atallah AN, Soares BG (2007). Passiflora for anxiety disorder. Cochrane Database of Systematic Reviews, (1), CD004518. — PubMed PMID: 17253512
- Pittler MH, Ernst E (2003). Kava extract for treating anxiety. Cochrane Database of Systematic Reviews, (1), CD003383. — PubMed PMID: 12535473
- Wolfman C, Viola H, Paladini A, Dajas F, Medina JH (1994). Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology Biochemistry and Behavior, 47(1), 1-4. — PubMed PMID: 7906886
- Dhawan K, Kumar S, Sharma A (2001). Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. Journal of Ethnopharmacology, 78(2-3), 165-170. — PubMed PMID: 11694362
- Dhawan K, Dhawan S, Chhabra S (2003). Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. Journal of Pharmacy & Pharmaceutical Sciences, 6(2), 215-222. — PubMed PMID: 12935433
- Grundmann O, Wähling C, Staiger C, Butterweck V (2009). Anxiolytic effects of a passion flower (Passiflora incarnata L.) extract in the elevated plus maze in mice. Pharmazie, 64(1), 63-64. — PubMed PMID: 19216234
- Soulimani R, Younos C, Jarmouni S, Bousta D, Misslin R, Mortier F (1997). Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Journal of Ethnopharmacology, 57(1), 11-20. — PubMed PMID: 9234160
- Akhondzadeh S, Mohammadi MR, Momeni F (2005). Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Therapy, 2(4), 609-614. (Not indexed in PubMed.)
- Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K (2020). Passiflora incarnata in neuropsychiatric disorders — a systematic review. Nutrients, 12(12), 3894. — PubMed PMID: 33352740
- Araújo JO, Bergamaschi CC, Lopes LC, Guimarães CC, de Andrade NK, Ramacciato JC, Motta RHL (2021). Effectiveness and safety of oral sedation in adult patients undergoing dental procedures: a systematic review. BMJ Open, 11(1), e043363. — PubMed PMID: 33495257
- Christoffoli MT, Bachesk AB, Farah GJ, Ferreira GZ (2021). Assessment of Passiflora incarnata L for conscious sedation of patients during the extraction of mandibular third molars: a randomized, split-mouth, double-blind, crossover study. Quintessence International, 52(10), 868-878. — PubMed PMID: 34076379
- Lima Neto TJ, Ribeiro NP, Souza MB, Freitas RN, Karande S, Mourão CF, Chaves-Neto AH, Faverani LP (2025). Effects of Passiflora incarnata on salivary biomarkers and anxiety in patients undergoing third molar extraction surgery. Scientific Reports, 15(1), 43616. — PubMed PMID: 41381570
PubMed Topic Searches
Connections
- All Herbs
- Passionflower Overview
- Passionflower Benefits Hub
- Passionflower for Sleep Quality
- Passionflower Gamma-Aminobutyric Acid Modulation
- Passionflower for Withdrawal
- Anxiety
- Depression
- Attention-Deficit/Hyperactivity Disorder
- Lavender
- Chamomile
- Lemon Balm
- Valerian
- Kava
- Magnesium
- Natural Anxiety Relief
- Stress Management
- History